SLC5A2 and hydrops fetalis: Three of them significantly reduce cardiovascular mortality/hospitalizations for HF among patients with eGFR <60 mL/min/m2 compared to placebo: sacubitril/valsartan, SGLT2 inhibitors (mainly dapagliflozin) and vericiguat.